Payment overview · 2025
General Payments
$191.05
5 reported records · 5 companies
Healthcare provider profile · identity verified
Mark R Key, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUBBOCK, TX · NPI 1861684441
Verified facts
What the public records show
CMS Open Payments records show Mark R Key, M.D. received $191.05 in general payments during 2025 across 5 reported records.
Aimmune Therapeutics, Inc. accounted for 62.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $120.18 | 62.9% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $24.30 | 12.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.27 | 9.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.25 | 8.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.05 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.05 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $120.18 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 563 | 165 |
| Metformin Hcl | Metformin Hcl | 346 | 102 |
| Lisinopril | Lisinopril | 321 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 298 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 278 | 79 |
| Gabapentin | Gabapentin | 258 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 83 |
| Allopurinol | Allopurinol | 236 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 223 | 165 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 63 |
| Furosemide | Furosemide | 203 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 55 |
| Pregabalin | Pregabalin | 179 | 38 |
| Potassium Chloride | Potassium Chloride | 165 | 56 |
| Losartan Potassium | Losartan Potassium | 159 | 53 |
| Meloxicam | Meloxicam | 159 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 47 |
| Omeprazole | Omeprazole | 150 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 52 |
| Eliquis | Apixaban | 134 | 29 |
| Atenolol | Atenolol | 127 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 121 | 39 |
| Clonazepam | Clonazepam | 113 | 17 |
| Glipizide | Glipizide | 113 | 35 |
| Simvastatin | Simvastatin | 110 | 31 |
| Jardiance | Empagliflozin | 109 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 36 |
| Prednisone | Prednisone | 102 | 76 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 26 |
| Alendronate Sodium | Alendronate Sodium | 94 | 31 |
| Ozempic | Semaglutide | 93 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 28 |
| Myrbetriq | Mirabegron | 91 | 23 |
| Tramadol Hcl | Tramadol Hcl | 90 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 51 |
| Donepezil Hcl | Donepezil Hcl | 69 | 15 |
| Trazodone Hcl | Trazodone Hcl | 69 | 20 |
| Tradjenta | Linagliptin | 67 | 16 |
| Cefdinir | Cefdinir | 65 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 15 |
| Ondansetron Odt | Ondansetron | 63 | 46 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 16 |
| Famotidine | Famotidine | 62 | 13 |
| Mirtazapine | Mirtazapine | 59 | 14 |
| Januvia | Sitagliptin Phosphate | 58 | 11 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 15 |
| Fluconazole | Fluconazole | 55 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 44 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 49 |
| Sucralfate | Sucralfate | 50 | 18 |
| Fenofibrate | Fenofibrate | 49 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 49 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 30 |
| Ezetimibe | Ezetimibe | 47 | 16 |
| Levofloxacin | Levofloxacin | 47 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Ibuprofen | Ibuprofen | 45 | 11 |
| Trulicity | Dulaglutide | 45 | 11 |
| Meclizine Hcl | Meclizine Hcl | 44 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Colchicine | Colchicine | 43 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 40 | suppressed |
| Estradiol | Estradiol | 40 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 13 |
| Movantik | Naloxegol Oxalate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 12 |
| Nystatin | Nystatin | 32 | 25 |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 20 |
| Valacyclovir | Valacyclovir Hcl | 32 | 19 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Nabumetone | Nabumetone | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 12 |
| Lactulose | Lactulose | 29 | 11 |
| Lidocaine | Lidocaine | 29 | 11 |
| Carvedilol | Carvedilol | 28 | 13 |
| Linzess | Linaclotide | 28 | 11 |
| Ramipril | Ramipril | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Mupirocin | Mupirocin | 23 | 21 |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Etodolac | Etodolac | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Naproxen | Naproxen | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.05 · 5 records | Aimmune Therapeutics, Inc. | LUMRYZ, MOUNJARO, VOQUEZNA, ZENPEP, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error